• Separating Growth Arrest from Cancer Cell Killing

  2026-09-23

  Hannah R. Schwartz’s dissertation argues that relative viability and fractional viability capture distinct components of anticancer drug response: changes in proliferation and cell killing. Its central practical lesson is to treat these measurements as complementary rather than interchangeable, while tracking how their relationship changes over time.

• Sulfo-NHS-Biotin for EV Protein Labeling

  2026-09-23

  Sulfo-NHS-Biotin enables aqueous, amine-selective labeling of intact cells, extracellular vesicles, and purified proteins without organic-solvent handling. This guide connects practical surface-protein workflows with EV-based targeted protein degradation studies, emphasizing controls that distinguish EV capture, protein abundance, and true target depletion.

• From DNA Synthesis to NSCLC Translation

  2026-09-22

  A mechanistic and translational framework for using EdU flow cytometry to connect CDK1–APE1 biology, cell-cycle pharmacodynamics, and NSCLC therapeutic strategy.

• Partial BACE1 Inhibition and Synaptic Transmission

  2026-09-22

  Satir et al. showed that moderate BACE inhibition can reduce amyloid-β secretion by up to 50% without impairing synaptic transmission in cultured rat cortical neurons, whereas stronger inhibition reduced both amyloid-β release and neuronal signaling. The study provides a useful exposure–response framework for Alzheimer’s disease research and cautions against treating maximal BACE1 suppression as the only therapeutic objective.

• Triazole ALDH2 Activators in Myocardial Ischemia

  2026-09-21

  The 2025 ACS Medicinal Chemistry Letters study developed triazole-based activators of aldehyde dehydrogenase 2 (ALDH2) to address oxidative aldehyde damage during myocardial ischemia–reperfusion. Molecular simulation guided the discovery of Z17, which showed strong ALDH2 activation, improved water-solubility characteristics, and protective effects on cardiac function and myocardial injury markers in mice.

• From FUBP1 Mechanism to Translational qPCR

  2026-09-21

  A mechanistic guide to translating FUBP1–FUSE biology into reproducible SYBR Green qPCR workflows, with strategic guidance for validating drug-response and gene-expression hypotheses.

• Oseltamivir Acid: From Mechanism to Translation

  2026-09-20

  A mechanism-first guide to using Oseltamivir acid in influenza antiviral research, resistance studies, and exploratory oncology workflows while keeping exposure, assay design, and translational limitations in view.

• Grazoprevir hydrate: HCV Assay Workflows

  2026-09-19

  Build sensitive, genotype-aware HCV replication assays with Grazoprevir hydrate (MK-5172 hydrate), from DMSO stock preparation through orthogonal antiviral and cytotoxicity readouts. The workflow emphasizes picomolar potency, vehicle control, resistance-aware comparisons, and practical troubleshooting for reproducible research results.

• Caffeine Workflows for Cancer and Metabolic Research

  2026-09-18

  Build reproducible Caffeine experiments around fresh aqueous stocks, concentration-response modeling, and orthogonal metabolic readouts. This guide distinguishes evidence-supported cancer cell line inhibition and obesity-model findings from practical assay extensions inspired by recent ALDH2 activator research.

• BRD4 Inhibition Enhances Erastin Ferroptosis

  2026-09-18

  A 2024 Discover Oncology study shows that BRD4 inhibition broadly sensitizes multiple cell lines to erastin-induced ferroptosis. Using pharmacological inhibitors, BRD4 knockdown, ROS analysis, ferroptosis-related gene profiling, and ChIP-sequencing, the authors identify ROS accumulation and FSP1 reduction as shared mechanistic features, while also revealing cell-specific transcriptional responses.

• Shufeng Xingbi Therapy in Allergic Rhinitis Rats

  2026-09-17

  This bioRxiv preprint examines how Shufeng Xingbi Therapy affects allergic rhinitis in OVA-sensitized rats by integrating nasal pathology, Th1/Th2-associated signaling, serum mediators, and intestinal microbiota. The findings support a gut–immune association, while the preclinical design and non-peer-reviewed status require cautious interpretation before clinical or mechanistic conclusions are drawn.

• BAF53a in Glioma: Prognosis, Invasion, and EMT

  2026-09-17

  The reference study identifies BAF53a as a prognostic biomarker candidate in glioma and links its expression to proliferation, invasion, and epithelial–mesenchymal transition. By combining patient-tissue analysis with gain- and loss-of-function experiments in U87 cells, the work provides a mechanistic framework for studying BAF53a in glioma progression while also highlighting important limits on clinical translation.

• From NLRC4 Biology to Translational qPCR

  2026-09-16

  A mechanistic and strategic guide to translating NLRC4 inflammasome biology into rigorous qPCR workflows, with practical guidance on assay design, SYBR Green chemistry, RNA-seq validation, and translational interpretation using HotStart™ 2X Green qPCR Master Mix.

• Medroxyprogesterone acetate: Decidualization Workflows

  2026-09-16

  Build reproducible MPA assays for endometrial decidualization, renal ion-channel signaling, and neurobiology. The workflow connects hormone exposure with fatty acid β-oxidation, lipid-droplet phenotyping, and receptor-mechanism controls.

• Mycobacterium tuberculosis WecA: Kinetic Study

  2026-09-15

  The reference study presents a practical strategy for producing soluble, assay-ready Mycobacterium tuberculosis WecA despite its challenging membrane topology. By combining regulated expression in Escherichia coli, affinity purification, mass-spectrometric identification, and UMP-based activity measurements, the authors establish a foundation for mechanistic studies and inhibitor evaluation.

8642 records 1/577 page Next 12345 下5页 Last page